Home › Funds › Velan Capital Investment Management LP › EPRX
Velan Capital Investment Management LP position in EPRX
EUPRAXIA PHARMACEUTICALS INC · Health Care
Velan Capital Investment Management LP reported holding 352,000 shares of EPRX (EUPRAXIA PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$3.2M, representing 3.06% of its reported portfolio and ranking #12 among its reported holdings. Velan Capital Investment Management LP has disclosed EPRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Velan Capital Investment Management LP's EPRX position evolved
Velan Capital Investment Management LP first disclosed a stake in EPRX in Q3 2025 at 352,000 shares (US$2.1M). The position peaked in Q3 2026 at 352,000 shares, worth US$3.2M. Across 5 filings, Velan Capital Investment Management LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 352,000 shares valued at US$3.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 352.00K | $2.08M | New |
| Q4 2025 | 352.00K | $2.66M | Hold |
| Q1 2026 | 352.00K | $2.55M | Hold |
| Q2 2026 | 352.00K | $2.33M | Hold |
| Q3 2026 | 352.00K | $3.20M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EPRX and 13F data
EPRX (EUPRAXIA PHARMACEUTICALS INC) is a Health Care company. 70 other funds we track also report a position in EPRX — the largest reported positions include Affinity Asset Advisors, LLC (US$15.6M), Vivo Capital, LLC (US$12.3M), PFM Health Sciences, LP (US$10.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EPRX
- Affinity Asset Advisors, LLC 1.72M sh · $15.62M · Q3 2026
- Vivo Capital, LLC 1.35M sh · $12.29M · Q3 2026
- PFM Health Sciences, LP 1.13M sh · $10.26M · Q3 2026
- GREAT POINT PARTNERS LLC 1.20M sh · $7.93M · Q2 2026
- Ikarian Capital, LLC 809.74K sh · $5.35M · Q2 2026
- Redmile Group, LLC 611.40K sh · $4.04M · Q2 2026
- Seven Fleet Capital Management LP 610.78K sh · $4.04M · Q2 2026
- Aisling Capital Management LP 325.00K sh · $2.96M · Q3 2026
- Ally Bridge Group (NY) LLC 252.18K sh · $1.67M · Q2 2026
- Delaney Capital Management Ltd. 112.40K sh · $1.03M · Q3 2026
- Lynx1 Capital Management LP 10.00K sh · $66.10K · Q2 2026
More on Velan Capital Investment Management LP
FAQ
How long has Velan Capital Investment Management LP held EPRX?
Velan Capital Investment Management LP has disclosed EPRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Velan Capital Investment Management LP's current position in EPRX?
As of Q3 2026, Velan Capital Investment Management LP holds 352.00K shares of EPRX (EUPRAXIA PHARMACEUTICALS INC), valued at $3.20M, representing 3.06% of its reported portfolio and ranking #12.
Has Velan Capital Investment Management LP been buying or selling EPRX?
In the latest 13F filing (Q3 2026), Velan Capital Investment Management LP held unchanged its position in EPRX. The position peaked in Q3 2026 at 352.00K shares.
Which other funds hold EPRX?
Other major institutional holders of EPRX include Affinity Asset Advisors, LLC, Vivo Capital, LLC, PFM Health Sciences, LP, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.